Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?

Chouchana Laurent; Beeker Nathanael; Treluyer Jean-Marc

首页> 外文期刊>JAIDS: Journal of acquired immune deficiency syndromes >Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?

【24h】

Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?

机译：怀孕期间是否存在用于DoluteGravir和整合酶抑制剂的安全信号？

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: Dolutegravir, an integrase strand transfer inhibitor (InSTI), is a major antiretroviral agent for HIV infection. Its use is promising, especially in low- and middle-income countries, because of a high resistance barrier and a good safety profile. Very recently, a World Health Organization safety signal has been raised regarding neural tube defects after the first-trimester exposure. Furthermore, to date, the experience is limited regarding the use of the other InSTI drugs (raltegravir and elvitegravir) during pregnancy. Our objective is to analyze the safety of InSTI drugs in pregnant women.

机译：背景：二硫韦，整合酶链转移抑制剂（insti）是用于艾滋病毒感染的主要抗逆转录病毒剂。它的使用是有前途的，特别是在低收入国家，因为高阻障和良好的安全性。最近，在第一三个月暴露后，在神经管缺陷上提出了世界卫生组织安全信号。此外，迄今为止，该经验有限于怀孕期间使用其他INSTI药物（RARTEGRAVIR和ELVITEGRAVIR）。我们的目的是分析孕妇血液植入药物的安全性。

著录项

来源
《JAIDS: Journal of acquired immune deficiency syndromes》 |2019年第4期|共6页
作者
Chouchana Laurent; Beeker Nathanael; Treluyer Jean-Marc;
展开▼
作者单位

Hop Cochin AP HP Ctr Reg Pharmacovigilance Paris France;

Univ Paris 05 Sorbonne Paris Cite Evaluat Therapeut &

Pharmacol Perinatale &

Pediat EA7323;

Hop Cochin AP HP Ctr Reg Pharmacovigilance Paris France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词
HIV; dolutegravir; raltegravir; elvitegravir; integrase inhibitors; pregnancy; birth defect; neural tube defect;

机译：艾滋病毒;Dolutegravir;Raltegravir;elvitegravir;整合酶抑制剂;妊娠;出生缺陷;神经管缺陷;

相似文献

外文文献
中文文献
专利

1. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy? [J] . Chouchana Laurent, Beeker Nathanael, Treluyer Jean-Marc JAIDS: Journal of acquired immune deficiency syndromes . 2019,第4期

机译：怀孕期间是否存在用于DoluteGravir和整合酶抑制剂的安全信号？
2. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV HIV ‐infected Patients: Efficacy, Safety and Tolerance [J] . Cid‐Silva Purificación, Llibre Josep M., Fernández‐Bargiela Noelia, Basic & clinical pharmacology & toxicology. . 2017,第Suppla1期

机译：艾滋病毒艾滋病毒患者中整合酶抑制剂Dolutigravir和Elvitegravir的临床经验：疗效，安全性和耐受性
3. Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV HIV ‐infected Patients: Efficacy, Safety and Tolerance [J] . Cid‐Silva Purificación, Llibre Josep M., Fernández‐Bargiela Noelia, Basic & clinical pharmacology & toxicology. . 2017,第5期

机译：艾滋病毒艾滋病毒患者中整合酶抑制剂Dolutigravir和Elvitegravir的临床经验：疗效，安全性和耐受性
4. Prediction of integrase inhibitor resistance from genotype through neural network modeling [C] . Xiaoyi Zhang, Yang Liu, Chengfei Hou, International Conference on Computer Science Education . 2016

机译：通过神经网络建模从基因型预测整合酶抑制剂的抗性
5. Green Chemical Synthesis of Amodiaquine, Purification, and Cocrystal Formation Studies of Piperine with HIV-1 Integrase Inhibitor: Dolutegravir [D] . Yeibyo, Woldegebriel G. 2020

机译：与HIV-1整合酶抑制剂的哌啶的绿色化学合成哌啶，纯化和哌啶的组合研究：DoluteGravir
6. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects [O] . Lynne M Mofenson, Anton L Pozniak, Jacque Wambui, 2019

机译：优化孕妇对药物安全信号的反应：以多洛格韦和神经管缺陷为例
7. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects [O] . Lynne M Mofenson, Anton L Pozniak, Jacque Wambui, 2019

机译：优化对怀孕药物安全信号的响应：DoluteGravir和神经管缺陷的例子

Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?

摘要

著录项

相似文献

相关主题

期刊订阅